Emergence of Innovative Facial Aesthetic Products Fuels North America Neurotoxins Market
The overall market for neurotoxins is expected to propel exponentially during the forecast period to meet the growing demand for facial aesthetics. In March 2022, Aquavit Pharmaceuticals, Inc. announced the submission of an Investigational New Drug (IND) of"DTX-021"-a botulinum toxin type A intended to treat moderate to severe glabellar lines. The product is a highly purified and clinically tested injectable neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum. Also, Aquavit is accelerating clinical trials by introducing DTX-022, and its final approval will be recognized as the first-of-its-kind and the world's first pan-facial microinjection of neurotoxins. Likewise, with the ongoing weight loss trend, Gastric Botox has become a popular choice among patients seeking non-invasive procedures. It involves injecting Botox into specific stomach regions using an endoscopic technique. By this technique, the contraction of the stomach muscles is restrained. Due to the limitation, the stomach's evacuation process takes longer, which causes the patient to feel full for longer period, resulting in reduced appetite and improved weight-related health issues/lifestyle disorders such as high blood pressure and diabetes mellitus. Therefore, emergence of innovative facial aesthetic products helps the North America neurotoxin market to grow.North America Neurotoxins Market Overview
The North America neurotoxin market is segmented into the US, Canada, and Mexico. The US is the largest and fastest-growing market for neurotoxins. The market growth in the region is attributed to the increasing product launches, growing FDA approvals for neurotoxins for various muscular conditions, rising aging population, increasing numbers of non-surgical or minimally invasive cosmetic procedures, increasing number of aesthetic procedures, and growing demand for minimally invasive therapeutics.North America Neurotoxins Market Revenue and Forecast to 2028 (US$ Million)
North America Neurotoxins Market Segmentation
The North America neurotoxins market is segmented into product type, application, end user, and country. Based on product type, the North America neurotoxins market is sub segmented into botox, dysport, xenomin, and others. The botox segment registered the largest market share in 2023.Based on application, the North America neurotoxins market is segmented into therapeutic and aesthetic. The therapeutic segment held a larger market share in 2023.
Based on end user, the North America neurotoxins market is segmented into hospitals, specialty clinics, dermatology clinics, and others. The hospitals segment held the largest market share in 2023.
Based on country, the North America neurotoxins market is segmented into the US, Canada, and Mexico. The US dominated the market share in 2023.
AbbVie Inc, Hugel Inc, Ipsen SA, Medytox Inc, Merz Pharma GmbH & Co KGaA, Metabiologics, and Revance Therapeutics Inc are among the leading companies operating in the North America neurotoxins market.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America neurotoxins market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the North America neurotoxins market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the neurotoxins market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
Table of Contents
Companies Mentioned
- AbbVie Inc
- Hugel Inc
- Ipsen SA
- Medytox Inc
- Merz Pharma GmbH & Co KGaA
- Metabiologics
- Revance Therapeutics Inc
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 99 |
Published | August 2023 |
Forecast Period | 2023 - 2028 |
Estimated Market Value in 2023 | 4801.29 Million |
Forecasted Market Value by 2028 | 8416.95 Million |
Compound Annual Growth Rate | 11.9% |
Regions Covered | North America |
No. of Companies Mentioned | 7 |